Literature DB >> 6184075

Human spleen cysteineproteinase inhibitor. Purification, fractionation into isoelectric variants and some properties of the variants.

M Järvinen, A Rinne.   

Abstract

The papain inhibitor from human spleen was purified by extraction in isotonic sucrose, acetone fractionation, papain-Sepharose affinity chromatography and gel filtration on Sephadex G-50. The purified inhibitor was fractionated by electrofocusing into four major isoelectric variants with pI values of 4.7, 5.0, 6.0 and 6.5. These variants can be classified into two groups: the acidic type, comprising the variants with pI 4.7 and 5.0, and the neutral type, comprising the variants with pI 6.0 and 6.5. The following properties distinguish the two types: 1. Immunological properties: antibodies raised against either of the neutral variants precipitated both of these, but not the acidic variants. The antiserum against the human epidermal cysteineproteinase inhibitor precipitated the acidic variants, but not the neutral variants. 2. Molecular size: two-dimensional electrophoresis of the purified inhibitor gave molecular weights of 11400 for the acidic variants and 12000 for the neutral variants. The pI 6.0 variant contained two compounds with molecular weights of 12000 and 12800. 3. Enzyme spectrum: human cathepsin B was inhibited by the acidic type, while the neutral type was a poor inhibitor. Both types inhibited cathepsin H, papain, ficin and bromelain, although the inhibition of bromelain did not exceed 70%. Human cathepsin D, bovine trypsin and chymotrypsin and porcine elastase were not inhibited by either type.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6184075

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  17 in total

1.  Purification and characterization of a cystatin-type cysteine proteinase inhibitor in the human hair shaft.

Authors:  H Tsushima; A Ueki; H Mine; N Nakajima; H Sumi; V K Hopsu-Havu
Journal:  Arch Dermatol Res       Date:  1992       Impact factor: 3.017

2.  Purification and characterization of high molecular mass and low molecular mass cystatin from goat brain.

Authors:  Sadia Sumbul; Bilqees Bano
Journal:  Neurochem Res       Date:  2006-10-25       Impact factor: 3.996

3.  Dendritic reticulum cells in AIDS-related lymphadenopathy.

Authors:  M Alavaikko; A Rinne; M Järvinen; V K Hopsu-Havu; P R Meyer; A M Levine; R J Lukes
Journal:  Experientia       Date:  1985-09-15

4.  Cysteine proteinase inhibitors in psoriatic epidermis.

Authors:  V K Hopsu-Havu; I A Joronen; M Järvinen; A Rinne
Journal:  Arch Dermatol Res       Date:  1983       Impact factor: 3.017

5.  Production of acid and neutral cysteine-proteinase inhibitors by a cultured human skin epithelium cell line.

Authors:  V K Hopsu-Havu; I Joronen; A Rinne; M Järvinen
Journal:  Arch Dermatol Res       Date:  1985       Impact factor: 3.017

6.  Cystatin-like cysteine proteinase inhibitors from human liver.

Authors:  G D Green; A A Kembhavi; M E Davies; A J Barrett
Journal:  Biochem J       Date:  1984-03-15       Impact factor: 3.857

7.  Immunolocalization of human cystatins in neutrophils and lymphocytes.

Authors:  M E Davies; A J Barrett
Journal:  Histochemistry       Date:  1984

8.  Isolation of cysteine proteinase inhibitor, cystatin A, from human nails.

Authors:  H Tsushima
Journal:  Arch Dermatol Res       Date:  1993       Impact factor: 3.017

9.  Cystatin. Amino acid sequence and possible secondary structure.

Authors:  C Schwabe; A Anastasi; H Crow; J K McDonald; A J Barrett
Journal:  Biochem J       Date:  1984-02-01       Impact factor: 3.857

Review 10.  Molecular background of progressive myoclonus epilepsy.

Authors:  Anna-Elina Lehesjoki
Journal:  EMBO J       Date:  2003-07-15       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.